A practical, hands-on guide to navigating deepfake technology and reducing the risks it poses to your business.
BRANCHBURG, N.J., March 10, 2026 /PRNewswire/ --Clordisys, headquartered in Branchburg, New Jersey, announces the publication of Chlorine Dioxide Medical Device Sterilization: Residual Toxicity ...
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of RaDaR® ST, its ...
We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology ...
The Python extension now supports multi-project workspaces, where each Python project within a workspace gets its own test tree and Python environment. This document explains how multi-project testing ...
Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...
New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...
MRD testing is underutilized in clinical practice due to uncertainty in its impact on patient management decisions. The MIDAS trial suggests omitting ASCT in multiple myeloma patients achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results